Nucleus-targeting Oxaplatin(IV) prodrug Amphiphile for enhanced chemotherapy and immunotherapy

Area of Science:

• Nanotechnology in Cancer Therapy
• Drug Delivery Systems
• Immunotherapy

Background:

• Platinum(II) drugs are widely used but face challenges with DNA targeting, leading to side effects and resistance.
• Current platinum(II) chemotherapy often exhibits suboptimal tumor accumulation and off-target toxicity.
• Developing advanced drug delivery systems is crucial for improving cancer treatment efficacy.

Purpose of the Study:

• To design and synthesize a novel platinum(IV) prodrug amphiphile for enhanced cancer therapy.
• To investigate the self-assembly of the prodrug into lipid nanoparticles for targeted delivery.
• To evaluate the synergistic effects of chemotherapy and immunotherapy in preclinical cancer models.

Main Methods:

• Development of a platinum(IV) prodrug amphiphile (C16-OPtIV-R8K) with lipid and peptide components.
• Self-assembly of the prodrug into uniform lipid nanoparticles (NTPtIV).
• In vitro and in vivo studies using cancer cells, 3D tumor spheres, and murine breast cancer models.

Main Results:

• NTPtIV demonstrated significantly higher platinum drug localization in cancer cell nuclei (74%) compared to oxaliplatin.
• Over a ten-fold increase in eliminating drug-resistant cancer cells was observed with NTPtIV.
• In vivo studies showed efficient tumor accumulation, suppressed tumor growth, and enhanced anti-tumor immunity via T cell recruitment.

Conclusions:

• The developed nucleus-targeted platinum(IV) nanoparticles offer a promising strategy for advanced cancer therapy.
• This approach synergistically enhances both chemotherapy and immunotherapy, leading to improved anti-cancer effects.
• The self-assembling nanoparticle system overcomes limitations of conventional platinum-based drugs.